로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > CD19:a validated therapeutic target for B-cell malignancies

CD19:a validated therapeutic target for B-cell malignancies

CD19:a validated therapeutic target for B-cell malignancies
Background

CD19 is a B-cell surface protein expressed throughout B-cell development and it is expressed on nearly all B-cell malignancies, including chronic lymphocytic leukemia (CLL), ALL, and many non-Hodgkin lymphomas. This specificity and universal expression for a single cell lineage has made CD19 an attractive target for antibody-based therapy, including bispecific antibodies, ADCs, Fc-engineered antibodies and CAR-T cell therapy. So far, two anti-CD19 CAR-T cell therapies and one bispecific anti-CD19/CD3 antibody have been approved by the FDA to treat hematologic B-cell malignancies. Till May 7, 2020, according to ClinicalTrials.gov, more than 763 clinical trials have been initiated.

To support the development of CD19-targeted antibody-based therapy, ACROBiosystems has developed a comprehensive series of CD19 protein products, including unconjugated CD19, biotinylated CD19 and fluorescent-labeled CD19. These proteins are suitable for immunization, antibody screening, antibody affinity measurement and detection of anti-CD19 CAR expression. The high activity of these proteins has been verified by ELISA, SPR and flow cytometry (FACS). Protocols are offered for free, which can help you save the development cycle.

ACROBiosystems has submitted DMF for its recombinant CD19 to FDA, and filed the DMF number as 034936. If our DMF filed CD19 proteins have been used in your drug development process, you can request that we provide DMF authorization to FDA in support of a submission or filing that you have made to the FDA. Please submit your request to ACROBiosystems by leaving your information here.Request for Authorization

Product List
MoleculeCat. No.HostProduct DescriptionStructure
>>> If you have FDA DMF filing request for other products, please contact us. Click here
Product Features

Detection of Anti-CD19 CAR Expression by FACS

FACS Analysis of Anti-CD19 CAR Expression
CD9-HP2H5-T1

5e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H5) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).

High Affinity Verified by SPR

Biotinylated Human CD19 (20-291), His, Avitag (Cat. No. CD9-H82E9) captured on Biotin CAP - Series S sensor Chip can bind FMC63 MAb (mouse lgG2a) with an affinity constant of 0.255 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Higher Binding Affinity than Competitive Products verified by ELISA, FACS and SPR

Binding activity of FITC-Labeled Human CD19, His Tag from two different vendors were evaluated in the ELISA analysis against FMC63 Mab. The result showed that ACRO's FITC-Labeled Human CD19, His Tag has a much higher binding activity than that of the other vendor.

Binding activity of FITC-Labeled Human CD19, His Tag from two different vendors were evaluated in the flow cytometry analysis against anti-CD19-CAR-293 cells. The result showed that ACRO's FITC-Labeled Human CD19, His Tag has a much higher binding activity than that of the other vendor.

Binding activity of Human CD19, His Tag from two different vendors were evaluated by SPR assay against FMC63 MAb. The result showed that ACRO's Human CD19, His Tag can bind FMC63 MAb with an affinity constant of 2.95 nM which is much higher than that of the other vendor.

More CD19 Related Products

If you have any customized request for CD19, just click here to tell us your needs.        
If you have any questions, suggestions or comments about CD19, please feel free to contact us bycart@acrobiosystems.com.

ACRO Quality

This web search service is supported by Google Inc.

totop